EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates

Michael Rainone, Saro Kasparian, Tina Nguyen, Neel Talwar, Yuan Yuan iD, Matthew Mei, Joanne E Mortimer, James R Waisman, Niki Patel, Vinod Pullarkat iD

The Oncologist · 07.09.2023 · 28 (9) · e843-e846

DOI: 10.1093/oncolo/oyad185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 19.06.2023. Verfasst von Michael Rainone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Thrombocytopenia, Anemia, Immunoconjugates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsThrombocytopeniaAnemiaImmunoconjugatesHumansFemaleAdo-Trastuzumab EmtansineReceptors, ThrombopoietinErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedTrastuzumab

Stichwörter der Autor:innen

HER2 positive breast canceravatrombopagromiplostimthrombocytopeniatrastuzumab deruxtecantrastuzumab emtansine

Substanzen

Ado-Trastuzumab EmtansineReceptors, ThrombopoietinErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedTrastuzumabImmunoconjugates

Autor:innen und Institutionen

  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

ORCID-Profile: Yuan Yuan, Vinod Pullarkat

Zitieren

APA

Rainone, M., Kasparian, S., Nguyen, T., Talwar, N., Yuan, Y., Mei, M., Mortimer, J. E., Waisman, J. R., Patel, N., & Pullarkat, V. (2023). Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates. The Oncologist, 28(9), e843-e846. https://doi.org/10.1093/oncolo/oyad185

Vancouver

Rainone M, Kasparian S, Nguyen T, Talwar N, Yuan Y, Mei M, et al. Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates. The Oncologist. 2023;28(9):e843-e846. doi:10.1093/oncolo/oyad185

BibTeX
@article{Rainone2023,
  author = {Rainone, Michael and Kasparian, Saro and Nguyen, Tina and Talwar, Neel and Yuan, Yuan and Mei, Matthew and Mortimer, Joanne E and Waisman, James R and Patel, Niki and Pullarkat, Vinod},
  title = {Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {9},
  pages = {e843--e846},
  doi = {10.1093/oncolo/oyad185}
}
Kostenlos starten →